18F-FDG PET/CT technology for the assessment of brown adipose tissue: an updated review

Expert Rev Med Devices. 2023 Jul-Dec;20(12):1143-1156. doi: 10.1080/17434440.2023.2283618. Epub 2023 Nov 24.

Abstract

Introduction: This review provides an update of 18 F-fluorodeoxyglucose ([18F] FDG) for Brown adipose tissue (BAT) activity quantification, whose role is not completely understood.

Areas covered: We conducted an unstructured search of the literature for any studies employing the [18F] FDG PET in BAT assessment. We explored BAT quantification both in healthy individuals and in different pathologies, after cold exposure and as a metabolic biomarker. The assessment of possible BAT modulators by using [18F] FDG PET is shown. Further PET tracers and novel developments for BAT assessments are also described.

Expert opinion: Further PET tracers and imaging modalities are under investigation, but the [18F] FDG PET is currently the method of choice for the evaluation of BAT and further multicentric trials are needed for a better understanding of the BAT physiopathology, also after cold stimuli. The modulation of BAT activity, assessed by [18F] FDG PET imaging, seems a promising tool for the management of conditions such as obesity and type 2 diabetes. Moreover, an interesting possible correlation of BAT activation with prognostic [18F] FDG PET indices in cancer patients should be assessed with further multicentric trials.

Keywords: BAT; BAT activity quantification; Brown adipose tissue; [18F] FDG-PET/CT; positron emission tomography.

Publication types

  • Review

MeSH terms

  • Adipose Tissue, Brown / diagnostic imaging
  • Adipose Tissue, Brown / metabolism
  • Diabetes Mellitus, Type 2* / metabolism
  • Fluorodeoxyglucose F18* / metabolism
  • Humans
  • Obesity
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods

Substances

  • Fluorodeoxyglucose F18